- Home
- CLDX
as 08-29-2025 4:00pm EST
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | HAMPTON |
| Market Cap: | 1.4B | IPO Year: | 2008 |
| Target Price: | $46.13 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.40 - $47.00 | Next Earning Date: | 08-07-2025 |
| Revenue: | $5,790,000 | Revenue Growth: | -30.27% |
| Revenue Growth (this year): | -44.09% | Revenue Growth (next year): | -10.65% |
Stock Insider Trading Activity of Celldex Therapeutics Inc. (CLDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Jimenez Freddy A. | CLDX | SVP & GENERAL COUNSEL | Aug 13 '25 | Sell | $24.68 | 771 | $19,095.91 | 35,392 |
Latest Celldex Therapeutics Inc. News
CLDX Breaking Stock News: Dive into CLDX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 months ago
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
GlobeNewswire
3 months ago
Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025
Zacks
3 months ago
Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?
GlobeNewswire
3 months ago
Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress
GlobeNewswire
3 months ago
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
Insider Monkey
4 months ago
Celldex Therapeutics, Inc. (CLDX): Among the Best Cancer Stocks to Invest in for Long-Term Gain
Zacks
4 months ago
Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates
Associated Press Finance
4 months ago
Celldex: Q1 Earnings Snapshot
Compare CLDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLDX Celldex Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.